Electroretinogram: a new human biomarker for smoking cessation treatment

视网膜电图：戒烟治疗的新人类生物标志物

• 批准号: 10180928
• 负责人: Sean Xiao Luo
• 金额: $ 19.98万
• 依托单位: NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-07-01 至 2023-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10180928
• 关键词: Abstinence; Address; Alcohol consumption; Amacrine Cells; Animal Experiments; Area; Attention deficit hyperactivity disorder; Behavior Therapy; Biological Markers; Brain; Clinical; Clinical Research; Clinical Trials; Cocaine Users; Collaborations; Cone; Corpus striatum structure; Data; Data Analytics; Development; Diagnosis; Disease; Dopamine; Dopamine D1 Receptor; Dopamine D2 Receptor; Dose; Early treatment; Electroretinography; Exhibits; Funding; Future; Gold; Grant; Human; Incentives; Individual; Knowledge; Light; Maintenance; Measures; Medicine; Mental disorders; Mentored Patient-Oriented Research Career Development Award; Mentors; Neurotransmitters; Nicotine Dependence; Oral; Participant; Patients; Pharmacological Treatment; Pharmacology; Physiology; Positron-Emission Tomography; Prediction of Response to Therapy; Protocols documentation; Proxy; Public Health; Records; Research; Research Methodology; Research Personnel; Retina; Rewards; Ritalin; Secure; Severities; Signal Transduction; Smoker; Smoking Cessation Intervention; Substance Use Disorder; Symptoms; Techniques; Testing; Tobacco Use Disorder; Tobacco smoking behavior; Tobacco use; Training Programs; Variant; Ventral Striatum; Writing; addiction; analytical method; base; biomarker development; career; cigarette smoking; cocaine use; contingency management; cost effectiveness; craving; financial incentive; genetic manipulation; global health; individual patient; individual variation; neuromechanism; neurotransmission; non-smoking; opioid use; outcome prediction; programs; psychostimulant; recruit; response; smoking cessation; substance use treatment; treatment response

Project Title: Electroretinogram: A New Human Biomarker for Smoking Cessation Treatment Project Summary: In this application for a K23 Mentored Patient Oriented Research Career Development Award, Dr. Sean Luo proposes a comprehensive plan for developing into an independent researcher to develop biomarkers in substance use disorders, and in particular, tobacco use disorder. Specifically, this proposal will focus on developing a new human biomarker, electroretinogram, for dopamine release. Tobacco smoking continues to be a major public health challenge. Several lines of evidence suggest that dopamine release deficit is involved in the development and maintenance of nicotine dependence. We hypothesize that those smokers who do not have a deficit in dopamine release will more likely respond to behavioral treatments for smoking cessation, and in particular, financial incentives contingent on abstinence (Contingency Management). Previous pilot data suggest that flash blue cone electroretinogram (ERG), which records electrical signals from the retina in response to light, is a clinically accessible correlate to dopamine release in the brain. We propose an ERG-based biomarker, and a pilot clinical trial to apply this biomarker to personalize smoking cessation treatment. This clinically tractable biomarker of central dopamine release may have a large number of future applications in the diagnosis and treatment of other mental illnesses and substance use disorders. While pursuing this line of research with the expertise of his mentors (Dr. Edward Nunes and Dr. Frances Levin) and preceptors (Drs. Diana Martinez, Stephen Tsang, Alan Budney and Jill Williams), Dr. Luo will concurrently engage in an individualized training program so as to develop in the following important areas: (1) retinal physiology and biomarker development (2) retinal data analytic methods (3) clinical research methods (4) behavioral and pharmacological treatment of tobacco use disorder (5) grant writing and administration.

项目名称：视网膜电信号：一种用于戒烟治疗的新型人体生物标志物 项目总结：在此申请K23指导下的以患者为导向的研究生涯发展 在获奖时，Sean Luo博士提出了一个全面的计划，以发展成为一名独立的研究人员 开发物质使用障碍，特别是烟草使用障碍的生物标记物。具体地说，这 该提案将专注于开发一种新的人类生物标记物--视网膜电信号，用于释放多巴胺。烟草 吸烟仍然是一个重大的公共卫生挑战。多条证据表明，多巴胺 释放缺陷与尼古丁依赖的形成和维持有关。我们假设 那些没有多巴胺释放缺陷的吸烟者更有可能对行为治疗有反应 戒烟，特别是以戒烟为条件的财政奖励(应急) 管理)。之前的飞行员数据表明，闪光蓝色视锥视网膜电信号(ERG)记录了 视网膜对光的反应的电信号，是临床上可以接触到的与多巴胺释放相关的 大脑。我们提出了一种基于ERG的生物标记物，并进行了一项试点临床试验，将该生物标记物应用于个性化 戒烟治疗。这种临床上易处理的中枢多巴胺释放的生物标志物可能有很大的 今后在诊断和治疗其他精神疾病和药物使用方面的应用数量 精神错乱。在他的导师(Edward Nunes博士和Dr.Edward Nunes博士)的专业知识下从事这方面的研究。 弗朗西斯·莱文)和导师(戴安娜·马丁内斯博士、曾俊华博士、艾伦·巴德尼博士和吉尔·威廉姆斯博士)、罗博士 将同时开展个性化培训计划，以便在以下重要领域发展： (1)视网膜生理学和生物标志物的发展(2)视网膜数据分析方法(3)临床研究 方法(4)烟草使用障碍的行为和药物治疗(5)赠款和 行政管理。